Search results
King Charles Returns to Duties After Cancer Treatment
US News & World Report· 2 days agoBritain's King Charles III is back to resuming his royal duties following treatment for cancer, Buckingham Palace announced Friday. On Tuesday, Charles and Queen Camilla are ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 8 hours agoAs Pepper Bio’s first in-licensed therapeutic, lerociclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). The therapeutic has previously demonstrated impressive ...
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the...
The Joplin Globe· 6 days ago("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its IFx ...
What’s going on with the ImmunityBio (IBRX) stock price?
Invezz· 2 days agoImmunityBio shares have been in a strong bull run this year, helped by the recent FDA approval of...
Music teacher’s ‘bump on the head’ turned out to be high-risk melanoma
PA Media: Science via Yahoo News· 6 days agoHe went to a private mole check clinic, where staff called him the next day and said “at best” the...
...Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of...
Denton Record-Chronicle· 2 days ago"The local coverage determination, or LCD, if finalized in its current form, would cause a significant, adverse impact on patient choice and access to care for the treatment of NMSC," DART President ...
...Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of...
FOX 23 News Albany· 2 days ago"The local coverage determination, or LCD, if finalized in its current form, would cause a significant, adverse impact on patient choice and access to care for the treatment of NMSC," DART President ...
Allogene secures $15 million grant for cancer trial By Investing.com
Investing.com· 5 days agoThe TRAVERSE trial follows the Fast Track Designation granted by the U.S...ALLO-316 to meet the...
Cancer drug trial provides lessons for future
Medical Xpress· 6 days agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according ...
Merck stock rises on sales of its blockbuster cancer drug Keytruda
Quartz· 6 days agoSales of Keytruda soared 20% in the first quarter of the year to $6.9 billion, compared with $5.8 billion in the same period last year. The U.S. Food and Drug first approved Keytruda in 2014 ...
